Lipocine Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Salt Lake City, Utah, leverages its proprietary Lip'iRal solubilization technology to develop differentiated oral drug delivery solutions for neuroendocrine, metabolic, endocrine, and central nervous system disorders. The company offers TLANDO, an FDA-approved oral testosterone replacement therapy for hypogonadism in adult males that does not require dose titration; LPCN 1111 (TLANDO XR), a next-generation once-daily oral prodrug of bioidentical testosterone in Phase 2 for testosterone replacement therapy; LPCN 1144, an oral prodrug of bioidentical testosterone that completed Phase 2 LiFT study for non-cirrhotic non-alcoholic steatohepatitis (NASH); LPCN 1148, an oral prodrug of testosterone for managing symptoms of decompensated cirrhosis including sarcopenia and hepatic encephalopathy, which received FDA Fast Track Designation; LPCN 1154 (BRLIZIO), an oral neurosteroid bioequivalent to IV brexanolone in pivotal studies for postpartum depression with Phase 3 trial ongoing and positive interim safety data; LPCN 1107, an oral hydroxyprogesterone caproate with orphan drug designation for preventing recurrent preterm birth; LPCN 2101, an oral candidate for epilepsy; LPCN 2401, a proprietary androgen receptor agonist for obesity management showing improved body composition in Phase 2; and LPCN 2203, an oral candidate for essential tremor. Lipocine operates primarily in the United States with a pipeline targeting large markets in endocrinology, hepatology, women's health, and CNS disorders through efficient 505(b)(2) regulatory pathways. Recent developments include licensing TLANDO commercialization rights to Verity Pharmaceuticals for the U.S. and Canada in January 2024 with up to $259 million in milestones and royalties up to 18%; distribution and license agreements with SPC Korea in October 2024 for South Korea commercialization and with Pharmalink in October 2024 for Gulf Cooperation Council countries; initiation of Phase 3 outpatient trial for LPCN 1154 in March 2025 with first patient dosed in June 2025 and promising DSMB safety review in November 2025; FDA labeling updates for testosterone products in March 2025; filing of New Drug Submission for TLANDO in Canada by Verity in June 2025; license and supply agreement for TLANDO in Brazil in May 2025; positive 52-week Phase 2 data for LPCN 1148 presented at EASL 2024; and publication of LPCN 1148 manuscript at The Liver Meeting 2024.
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Mangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast
John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock
What's Going On With Lipocine Stock On Monday?
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
2026 Asset Growth: Why Federal Compliance Is the New Metric
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL)